help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2005-1441
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLaughlin, T.
Right arrow Articles by Tsao, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLaughlin, T.
Right arrow Articles by Tsao, P. S.
Related Collections
Right arrow Female Endocrinology
Right arrow Metabolism
Right arrow Obesity
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 5 1896-1900
Copyright © 2006 by The Endocrine Society

Plasma Asymmetric Dimethylarginine Concentrations Are Elevated in Obese Insulin-Resistant Women and Fall with Weight Loss

Tracey McLaughlin, Markus Stühlinger, Cindy Lamendola, Fahim Abbasi, Joan Bialek, Gerald M. Reaven and Philip S. Tsao

Divisions of Endocrinology (T.M.) and Cardiovascular Medicine (F.A., G.M.R., P.S.T., J.B., C.L.), Stanford University School of Medicine, Stanford, California 94305-5103; and Universitaetsklinik fuer Innere Medizin (M.S.), 6020 Innsbruck, Austria

Address correspondence and requests for reprints to: Dr. Philip S. Tsao, Ph.D., Stanford University, Falk Building, 300 Pasteur Drive, Stanford, California 94305-5103. E-mail: ptsao{at}cvmed.stanford.edu.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Context: Plasma asymmetric dimethylarginine (ADMA) concentrations are higher in apparently healthy, insulin-resistant (IR) individuals and decrease in response to thiazolidenedione treatment.

Objective: The objective of the study was to determine whether ADMA concentrations would also fall when insulin sensitivity is enhanced with weight loss in obese individuals.

Design/Setting/Patients/Intervention: Twenty obese women classified as IR or insulin sensitive (IS) on the basis of their steady-state plasma glucose (SSPG) concentration during the insulin suppression test underwent 12 wk of dietary weight loss.

Outcome Measures: Plasma glucose, insulin, and ADMA were measured at baseline and after weight loss; change in insulin resistance was quantified by repeating the SSPG after the dietary intervention.

Results: Although weight loss was similar in the two groups, significant improvements in SSPG, glucose, and insulin concentrations were confined to the IR group. Baseline plasma ADMA concentrations (mean ± SD) were higher in IR subjects (1.69 ± 0.44 vs. 1.18 ± 0.45 µmol/liter, P = 0.02) and decreased to 1.20 ± 0.22 µmol/liter (P < 0.001) with weight loss. In contrast, ADMA levels did not change with a similar extent of weight loss in the IS group.

Conclusion: Plasma ADMA levels are higher in obese, IR women than in equally obese, IS women and decrease in response to weight loss when associated with enhancement of insulin sensitivity.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
PLASMA CONCENTRATIONS OF asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (1), are elevated in several clinical syndromes associated with insulin resistance and increased cardiovascular disease (CVD) risk (2, 3, 4, 5, 6, 7, 8, 9). We have recently shown that plasma ADMA concentrations were also elevated in apparently healthy, insulin-resistant (IR) individuals and that treatment of these subjects with the thiazolidenedione (TZD) compound, rosiglitazone, resulted in both enhanced insulin sensitivity and a fall in plasma ADMA concentration (10). Although these findings were consistent with the notion that insulin resistance and compensatory hyperinsulinemia were responsible for the elevated plasma ADMA concentrations, the actions of TZD compounds are not limited to improving insulin sensitivity (11), and it is possible that the rosiglitazone-induced decrease in plasma ADMA concentrations could have resulted from direct effect of the drug, unrelated to its ability to enhance insulin sensitivity.

The present study, initiated to extend the observations discussed above, addressed the following two questions: 1) would plasma ADMA concentrations be elevated in IR individuals, compared with insulin-sensitive (IS) persons when both groups were obese; and 2) would elevated plasma ADMA concentrations in IR individuals also fall when insulin sensitivity was enhanced by nonpharmacological means? To answer these questions we took advantage of the fact that insulin sensitivity improves when obese, IR individuals lose weight but does not change with weight loss in IS, obese individuals (12, 13). Therefore, we compared plasma ADMA concentrations in equally obese women, divided into IR and IS subgroups, and repeated the measurements of both insulin sensitivity and ADMA concentrations after weight loss. The results demonstrated that plasma ADMA concentrations were higher at baseline in the IR, obese individuals and that weight loss in this group was associated with both an improvement in insulin sensitivity and a decrease in plasma ADMA concentrations. In contrast, neither variable changed when IS, obese persons lost weight. These findings provide additional evidence that plasma ADMA concentrations are increased in IR individuals and demonstrate that they will decline when insulin sensitivity is improved by nonpharmacological means.


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
The study population consisted of volunteers from the San Francisco Bay Area who responded to newspaper advertisements seeking healthy, overweight women interested in weight loss. All potential subjects gave written, informed consent to participate in weight loss studies approved by the Stanford Human Subjects Committee. Subjects were required to have a body mass index between 29 and 35 kg/m2, to be in apparently good health, to be nonpregnant and nonlactating, to have stable weight and no history of eating disorder or endocrine cause of obesity, and to have fasting plasma glucose less than 126 mg/dl. No subjects were taking blood pressure or lipid-lowering medications.

Insulin-mediated glucose disposal was quantified by a modification (14) of the insulin suppression test as originally described and validated (15, 16). Briefly, subjects were infused for 180 min with octreotide (0.27 µg/m2·min), insulin (32 mU/m2·min), and glucose (267 mg/m2·min). Blood was drawn at 10-min intervals from 150 to 180 min of the infusion to measure the plasma glucose and insulin concentrations, and the average of these four values was considered to represent the steady-state plasma insulin (SSPI) and glucose (SSPG) concentrations for each individual. Because SSPI concentrations are similar in all subjects, the SSPG concentration provides a direct measure of the relative ability of insulin to mediate disposal of an infused glucose load: the higher the SSPG concentration, the more IR the individual.

Based on the SSPG concentrations during the insulin suppression test, subjects who qualified as IR or IS (but not intermediate) were eligible to proceed with the dietary weight loss intervention. Whereas insulin-mediated glucose disposal varies continuously in healthy nondiabetic individuals, precluding an objective definition of an individual as being either IS or IR (17), we previously demonstrated that CVD developed to a significantly greater degree in the third of the healthy subject population that was the most IR (18, 19). Thus, for the purposes of this study, we defined individuals with SSPG concentrations in the top tertile of the distribution observed in 490 healthy volunteers (including normal weight) (17) as IR and those in the lowest tertile as IS. Plasma was obtained after an overnight fast for measurement of fasting plasma L-arginine and ADMA concentrations as previously described (3, 10).

After baseline measurement (3, 10) of plasma ADMA concentrations in the IR and IS groups, we measured plasma glucose and insulin responses to standardized test meals comprising (as percent calories) 42% carbohydrate, 43% fat, and 15% protein. The meals were given at 0800 h (20% of daily caloric requirement) and 1200 h (40% of daily caloric requirement), and blood was drawn for measurement of plasma glucose and insulin concentrations before the meal at 0800 h and then at hourly intervals for 8 consecutive hours. Daylong glucose and insulin responses were calculated, using the trapezoidal method, as the area under the curve of the nine time points, with equal weighting of each time point. These values, along with individual time points were used for statistical analyses as described below.

The dietary intervention consisted of a 12-wk period of weight loss via hypocaloric diet. Subjects were individually instructed on a calorie-restricted diet, using the Harris-Benedict equation (20) for resting energy requirements, multiplied by an activity factor, less 1000 kcal/d, to produce a weight loss of approximately 0.9 kg/wk. For all subjects, macronutrient composition of the diets was 42% carbohydrate, 43% fat, and 15% protein. Subjects met with research nutritionists at weekly intervals during the dietary period to enhance compliance and evaluate progress of weight loss. At these visits subjects were also reminded to maintain their usual level of physical activity (to minimize possible confounding by changes in exercise level), and were questioned as to any changes. After completion of the weight-loss phase, subjects were assigned a weight-maintenance diet for 2 wk before repeating the baseline measurements described above. Only those volunteers who completed the study and lost at least 5% of initial body weight are included in the present analysis.

The results are expressed as mean ± SD. Student’s unpaired t test (two tailed) was used to evaluate the statistical significance of baseline differences between the IR and IS groups. Due to small numbers, women who were premenopausal and/or took estrogen replacement were combined for comparison with postmenopausal women (without estrogen replacement), defined as cessation of menses for at least 1 yr. Fisher’s exact test was used to compare the menopausal hormone status. Student’s paired t test was used to evaluate the change in ADMA, weight, and SSPG within each group. ANOVA was used to compare the change in ADMA, with group (IR vs. IS) as the main effect and percent weight change and baseline ADMA as covariates. Daylong insulin and glucose values were compared at baseline (between groups) and before and after weight loss (within groups) via repeated-measures ANOVA. Pearson’s correlation coefficients were calculated to assess the potential association between change in SSPG, daylong insulin response (area under the curve), weight, and change in ADMA concentrations. P < 0.05 was considered statistically significant. All analyses were done with Systat (version 10.2; Richmond, CA).


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
SSPG concentrations were determined in 84 volunteers; 65 classified as being either IR or IS by the criteria defined in Subjects and Methods. Forty-four of these individuals completed the weight-loss study, and the results of 20 volunteers (10 IR and 10 IS) who lost at least 5% of initial body weight were included in the current analysis. The baseline characteristics of the two experimental groups are shown in Table 1Go, and it is clear that the only significant difference between them was their SSPG concentrations. None of the subjects engaged in strenuous physical activity (e.g. marathon training), and they were requested to maintain the current level of activity throughout the study duration.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Baseline characteristics of IR and IS obese women (mean ± SD)

 
Figure 1Go indicates that both the IR and IS groups lost a statistically significant amount of weight (8.6 ± 3.9 kg, 10.3%, and 7.3 ± 2.8 kg, 8.7%, respectively), and the amount of weight lost did not differ significantly between groups. Figure 1Go also demonstrates that SSPG concentration decreased in association with weight loss by 42% in the IR group (P < 0.001), whereas the values were similar before and after weight loss in IS individuals. Although insulin sensitivity was clearly enhanced with weight loss in the IR subjects, it should be noted that their SSPG concentrations after weight loss were still higher than those of IS individuals.


Figure 1
View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1. Weight (left) and SSPG concentrations (right) before and after weight loss in IR and IS obese women. Values shown are mean ± SEM. For conversion of SSPG to SI units, multiply by 0.0556 (millimoles per liter). P = NS for comparison of change in weight between IR and IS groups. SSPI concentrations in IR and IS subjects at baseline were 52 ± 16 vs. 54 ± 15 µU/ml, respectively (P = 0.68) and after weight loss 52 ± 11 vs. 46 ± 3 µU/ml (P = 0.21).

 
Daylong plasma glucose and insulin concentrations are shown in Fig. 2Go. The baseline daylong glucose response was similar in the two groups (P = 0.32), and weight loss did not lead to a significant decline in glucose concentrations in either the IR (P = 0.24) or IS (P = 0.69) group.


Figure 2
View larger version (31K):
[in this window]
[in a new window]
  		FIG. 2. Daylong insulin concentrations in IR (A) and IS (B) women before (solid line) and after (broken line) weight loss; daylong glucose concentrations in IR (C) and IS (D) obese women before and after weight loss. Values shown are mean ± SEM. For conversion to SI units, multiply by 0.0556 for glucose (millimoles per liter) and 7.175 for insulin concentrations (picomoles per liter).

 
Figure 2Go also illustrates the impact of weight loss on the daylong insulin response of the two groups. It is obvious that baseline plasma insulin concentrations were higher in the IR subjects (repeated measures ANOVA, P = 0.005) and that they decreased significantly when these individuals lost weight (repeated measures ANOVA, P = 0.047). In contrast, there was no significant change in the daylong insulin response after weight loss in the IS group. Similar to the changes in SSPG concentration, daylong plasma insulin levels in the IR subjects declined to a value approximately halfway between where they were at baseline and the values in the IS subjects.

Plasma ADMA concentrations before and after weight loss in the two experimental groups are shown in Fig. 3Go. These results demonstrate that plasma ADMA concentrations were significantly higher (P = 0.02) in the IR women (1.69 ± 0.44 µmol/liter) than the equally obese, IS women (1.18 ± 0.45 µmol/liter). Furthermore, ADMA concentrations declined significantly in association with weight loss (P < 0.001) in the IR group, whereas they did not change in the IS group. Even after adjustment for percent weight change and baseline ADMA concentrations, as compared with the IS group, the IR group experienced a significantly greater decline in ADMA concentrations (P = 0.028). As a result, plasma ADMA levels after weight loss were identical in the IR (1.20 ± 0.22 µmol/liter) and IS (1.20 ± 0.60 µmol/liter) groups.


Figure 3
View larger version (28K):
[in this window]
[in a new window]
  		FIG. 3. Plasma ADMA concentrations before and after weight loss in IR and IS obese women. Values shown are mean ± SEM.

 
In addition to having higher plasma ADMA concentrations, the plasma L-arginine to ADMA concentration ratio was significantly lower in the IR subjects at baseline (48.1 ± 13 vs. 74.4 ± 31.8, P < 0.05). Unlike ADMA concentrations, weight loss did not lead to statistically significant changes in L-arginine concentrations. Consequently, the plasma L-arginine to ADMA concentration ratio increased in the IR subjects but not the IS subjects, resulting in the difference between the two groups being no longer statistically significant (63.0 ± 13.5 vs. 79.8 ± 44.9).

The relationships between the change in ADMA and the change in SSPG, daylong plasma insulin concentration, and body weight in the entire study population are shown in Fig. 4Go. It is apparent that there was a significant association between the decline in insulin resistance (SSPG) and the fall in ADMA concentration (r = 0.70, P = 0.001) and a significant association of lesser magnitude between the decrease in daylong plasma insulin concentrations and the decline in ADMA concentration (r = 0.48, P = 0.04). On the other hand, there was no correlation between the amount of weight lost and the fall in plasma ADMA concentration.


Figure 4
View larger version (15K):
[in this window]
[in a new window]
  		FIG. 4. Pearson’s correlation coefficients among change in SSPG (A), daylong insulin concentration (measured as area under the curve) (B), and weight (C) and change in plasma ADMA concentration. For conversion to SI units, multiply SSPG by 0.0556 (millimoles per liter) and insulin by 7.175 (picomoles per liter).

 

   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
The results of the current study demonstrate that obese, apparently healthy women who are IR have higher plasma ADMA concentrations than do equally obese, apparently healthy women who are IS. When considered in conjunction with our earlier findings (10), we have now demonstrated that plasma ADMA concentrations are higher in IR, compared with IS, nonobese men and women, obese women, and patients with essential hypertension. The fact that plasma ADMA concentrations are also elevated in patients with type 2 diabetes, CVD, and renal failure (2, 3, 4, 5, 7), clinical syndromes known to be associated with insulin resistance (6, 8, 9), lends further support for the existence of a relationship between insulin resistance and increases in plasma ADMA concentrations.

The results of this study expand our understanding of the complex relationship between obesity, insulin resistance, endothelial dysfunction, and CVD. At the simplest level, they provide further evidence that the prevalence of CVD risk factors varies significantly in obese individuals as a function of their degree of insulin sensitivity. Thus, we have previously shown that glucose intolerance, hyperinsulinemia, dyslipidemia, and elevated levels of C-reactive protein occur primarily in those obese individuals who are also IR (13, 14). The current study extends these earlier findings and provides evidence that elevated ADMA concentrations should be added to the list of CVD risk factors that occur primarily in the subset of obese individuals that are also IR.

In the current study, we showed that weight loss with concurrent enhancement of insulin sensitivity leads to a substantial and statistically significant decline in ADMA concentration among IR individuals. In essence, the ADMA concentrations in these individuals were normalized to those of their IS counterparts, even though their insulin sensitivity did not improve to the same degree. This finding is important for two reasons. First, it suggests a mechanism by which weight loss may lead to enhanced endothelial function and lower CVD risk. Second, the current findings extend those of our prior study, in which we found that enhancement of insulin sensitivity with TZD treatment (10) is capable of decreasing plasma ADMA concentrations. Thus, the current results, in which we used a different means of enhancing insulin action weight loss, provide support for the hypothesis that reductions in ADMA in the prior study were a function of enhanced insulin action rather than a direct drug effect. Our results are strengthened by the use, in the current study, of a control group of equally obese individuals who were not IR at baseline and who did not experience a change in insulin action despite weight loss similar in magnitude to that seen in the IR group. The fact that in the IS group, ADMA concentrations were low to begin with and did not change with weight loss suggests that insulin resistance, rather than obesity per se, is a potential mediator of ADMA concentrations. Thus, the results of our two studies strongly suggest that insulin resistance is associated with elevations in ADMA concentrations and that enhanced insulin sensitivity, irrespective of the specific intervention, has the ability to lower ADMA concentrations.

Although recognition of the importance of elevated plasma ADMA concentrations as indicating increased CVD risk is relatively recent, the evidence that this is the case is accumulating rapidly (7, 21, 22, 23). Furthermore, the biological function of ADMA, competitive inhibition of nitric oxide synthase bioactivity, provides a logical explanation by which ADMA potentiates CVD risk. In addition to its action as a vasodilator, nitric oxide inhibits platelet aggregation, leukocyte adhesion, proliferation of vascular smooth muscle, and endothelial generation of superoxide anion, all of which are key processes in atherogenesis (24). Although it is tempting to speculate that endothelial function would improve when plasma ADMA concentrations fall in overweight, IR individuals, this functional variable was not quantified in our study. However, results of several previous weight-loss studies (25, 26, 27, 28), using a variety of different experimental protocols, have concluded that endothelial vasodilatory function improves in association with weight loss. Thus, the observed improvement in ADMA concentrations and resultant L-arginine to ADMA ratios described in this study when IR volunteers lost weight provides a unifying explanation for this beneficial effect.

In conclusion, the current results, taken together with our previous findings, indicate that plasma ADMA concentrations are elevated in IR, hyperinsulinemic individuals and that they decrease significantly in association with enhanced insulin sensitivity. These observations emphasize the potential clinical benefit of interventions that improve insulin sensitivity and decrease plasma ADMA concentrations. Indeed, elevations in ADMA may represent a reversible abnormality that contributes to the increased CVD risk seen in IR individuals.


   Footnotes
 
This work was supported by National Institutes of Health Grants RR2HLL406, RR 000070, RR16071-01, and 1RO1HL73084-01.

T.M., M.S., C.L., F.A., J.B., G.M.R., and P.S.T. have nothing to declare.

First Published Online February 28, 2006

Abbreviations: ADMA, Asymmetric dimethylarginine; CVD, cardiovascular disease; IR, insulin-resistant; IS, insulin-sensitive; SSPG, steady-state plasma glucose; SSPI, steady-state plasma insulin; TZD, thiazolidenedione.

Received June 29, 2005.

Accepted February 16, 2006.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Vallance P, Leone A, Calver A, Collier J, Moncada S 1992 Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20(Suppl 12):S60–S62
  2. Vallance P, Leone A, Calver A, Collier J, Moncada S 1992 Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572–575[CrossRef][Medline]
  3. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM 2001 Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88:1201–1203[CrossRef][Medline]
  4. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC 1999 Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33:652–658[CrossRef][Medline]
  5. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC 1999 Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594–600[Abstract/Free Full Text]
  6. Reaven GM, Weisinger JR, Swenson RS 1974 Insulin and glucose metabolism in renal insufficiency. Kidney Int Suppl 63–69
  7. Vallance P 2001 Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358:2096–2097[CrossRef][Medline]
  8. Reaven GM 1988 Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607[Abstract]
  9. Zavaroni I, Bonini L, Gasparini P, Barilli AL, Zuccarelli A, Dall’Aglio E, Delsignore R, Reaven GM 1999 Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 48:989–994[CrossRef][Medline]
  10. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS 2002 Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420–1426[Abstract/Free Full Text]
  11. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K 2003 Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493–2499[Abstract/Free Full Text]
  12. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G 2001 Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism 50:795–800[CrossRef][Medline]
  13. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P 2002 Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106:2908–2912[Abstract/Free Full Text]
  14. Pei D, Jones CN, Bhargava R, Chen YD, Reaven GM 1994 Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 37:843–845[CrossRef][Medline]
  15. Shen SW, Reaven GM, Farquhar JW 1970 Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 49:2151–2160[Medline]
  16. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G 1981 Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 30:387–392[Abstract]
  17. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM 2000 Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 23:171–175[Abstract]
  18. Yip J, Facchini FS, Reaven GM 1998 Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83:2773–2776[Abstract/Free Full Text]
  19. Facchini FS, Hua N, Abbasi F, Reaven GM 2001 Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86:3574–3578[Abstract/Free Full Text]
  20. Harris JA, Benedict FG 1919 A biometric study of basal metabolism in man. Washington, DC: Carnegie Institute of Washington
  21. 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497
  22. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R 2001 Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113–2117[CrossRef][Medline]
  23. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R; CREED Investigators 2002 Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62:339–345[CrossRef][Medline]
  24. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R 2001 Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127–2128[CrossRef][Medline]
  25. Tsao PS, Cooke JP 1998 Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. J Cardiovasc Pharmacol 32(Suppl 3):S48–S53
  26. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D’Andrea F, Molinari AM, Giugliano D 2002 Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105:804–809[Abstract/Free Full Text]
  27. Sciacqua A, Candigliota M, Ceravolo R, Scozzafava A, Sinopoli F, Corsonello A, Sesti G, Perticone F 2003 Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care 26:1673–1678[Abstract/Free Full Text]
  28. Sekuri C, Tavli T, Avsar A, Sozcuer H, Uyanik BS, Ari Z 2003 The acute effect of orlistat on endothelial function in young obese women. Int J Clin Pharmacol Res 23:111–117[Medline]



This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
M. C. Cave, R. T. Hurt, T. H. Frazier, P. J. Matheson, R. N. Garrison, C. J. McClain, and S. A. McClave
Obesity, Inflammation, and the Potential Application of Pharmaconutrition
Nutr Clin Pract, February 1, 2008; 23(1): 16 - 34.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. I. Yilmaz, A. Sonmez, M. Saglam, A. R. Qureshi, J. J. Carrero, K. Caglar, T. Eyileten, E. Cakir, Y. Oguz, A. Vural, et al.
ADMA Levels Correlate with Proteinuria, Secondary Amyloidosis, and Endothelial Dysfunction
J. Am. Soc. Nephrol., February 1, 2008; 19(2): 388 - 395.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Heutling, H. Schulz, I. Nickel, J. Kleinstein, P. Kaltwasser, S. Westphal, F. Mittermayer, M. Wolzt, K. Krzyzanowska, H. Randeva, et al.
Asymmetrical Dimethylarginine, Inflammatory and Metabolic Parameters in Women with Polycystic Ovary Syndrome before and after Metformin Treatment
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 82 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. C. Ryan, F. Abbasi, C. Lamendola, S. Carter, and T. L. McLaughlin
Serum Alanine Aminotransferase Levels Decrease Further With Carbohydrate Than Fat Restriction in Insulin-Resistant Adults
Diabetes Care, May 1, 2007; 30(5): 1075 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
T. McLaughlin, F. Abbasi, C. Lamendola, and G. Reaven
Heterogeneity in the Prevalence of Risk Factors for Cardiovascular Disease and Type 2 Diabetes Mellitus in Obese Individuals: Effect of Differences in Insulin Sensitivity
Arch Intern Med, April 9, 2007; 167(7): 642 - 648.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLaughlin, T.
Right arrow Articles by Tsao, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLaughlin, T.
Right arrow Articles by Tsao, P. S.
Related Collections
Right arrow Female Endocrinology
Right arrow Metabolism
Right arrow Obesity

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals